JY
MNPR icon

Jeff Yass’s Monopar Therapeutics MNPR Stock Holding History

Jeff Yass’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,137
Closed -$227K – 14114
2026
Q1 		$227K Buy
+4,137
New +$250K ﹤0.01% 11460
2025
Q4 		– Sell
-4,328
Closed -$353K – 13121
2025
Q3 		$353K Sell
4,328
-4,028
-48% -$180K ﹤0.01% 9739
2025
Q2 		$299K Buy
+8,356
New +$303K ﹤0.01% 10343
2024
Q1 		– Sell
-2,199
Closed -$3.74K – 12891
2023
Q4 		$3.74K Buy
2,199
+107
+5% +$217 ﹤0.01% 12143
2023
Q3 		$5.96K Buy
+2,092
New +$7.31K ﹤0.01% 11769
2022
Q4 		– Sell
-2,117
Closed -$16K – 13197
2022
Q3 		$16K Buy
+2,117
New +$20.1K ﹤0.01% 12672

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Jeff Yass's MNPR Position: Q2 2026 in Review

Jeff Yass sold out of Monopar Therapeutics (MNPR) in Q2 2026, closing a stake of 4,137 shares — an estimated $227K sold.

Jeff Yass first reported a position in MNPR in Q3 2022 and held it in 6 quarters. The position peaked at $353K in Q3 2025. 95 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Jeff Yass reported no remaining Monopar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 4,137 Monopar Therapeutics shares in Q2 2026, an estimated $227K.
  • Jeff Yass first reported a position in Monopar Therapeutics in Q3 2022 and held it in 6 quarters.
  • Jeff Yass's Monopar Therapeutics position peaked at $353K in Q3 2025.
  • 95 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.